KINNATE BIOPHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.65 USD | -0.38% |
|
-.--% | +11.81% |
| 03/04 | Kinnate Biopharma Inc. Announces Board Resignations | CI |
| 03/04 | Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 1,724 | 774.3 | 269.4 | 111.7 |
| Enterprise Value (EV) 1 | 1,327 | 415.8 | 7.248 | -49.46 |
| P/E ratio | -7.53 x | -8.61 x | -2.31 x | -0.98 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -3,69,36,822 x | -46,20,558 x | -61,463 x | 4,18,419 x |
| EV / FCF | -7,71,30,730 x | -1,06,17,201 x | -1,42,619 x | 8,34,896 x |
| FCF Yield | -0% | -0% | -0% | 0% |
| Price to Book | 4.4 x | 2.43 x | 1.21 x | 0.7 x |
| Nbr of stocks (in thousands) | 43,327 | 43,696 | 44,165 | 47,113 |
| Reference price 2 | 39.78 | 17.72 | 6.100 | 2.370 |
| Announcement Date | 29/03/21 | 28/03/22 | 15/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | -35.92 | -89.99 | -117.9 | -118.2 |
| EBIT 1 | -7.63 | -12.01 | -36 | -90.11 | -118.5 | -119 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.63 | -9.938 | -35.76 | -89.76 | -116.3 | -112.6 |
| Net income 1 | -7.63 | -9.938 | -35.76 | -89.76 | -116.3 | -112.6 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -2.091 | -2.716 | -5.284 | -2.059 | -2.639 | -2.419 |
| Free Cash Flow | - | -5.91 | -17.2 | -39.16 | -50.82 | -59.24 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 03/11/20 | 03/11/20 | 29/03/21 | 28/03/22 | 15/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7 | 76.5 | 397 | 359 | 262 | 161 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -5.91 | -17.2 | -39.2 | -50.8 | -59.2 |
| ROE (net income / shareholders' equity) | - | -23.9% | -15.3% | -24% | -37.9% | -53.9% |
| ROA (Net income/ Total Assets) | - | -17.5% | -9.41% | -14.7% | -22.9% | -32.9% |
| Assets 1 | - | 56.71 | 380 | 611.6 | 506.7 | 342.6 |
| Book Value Per Share 2 | 2.090 | -4.770 | 9.050 | 7.280 | 5.040 | 3.380 |
| Cash Flow per Share 2 | 1.920 | 20.90 | 8.410 | 3.410 | 1.240 | 1.210 |
| Capex | - | - | 0.3 | 0.77 | 2.72 | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 03/11/20 | 03/11/20 | 29/03/21 | 28/03/22 | 15/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +11.81% | 125M | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| -1.24% | 11.8B |
- Stock Market
- Equities
- KNTE Stock
- Financials Kinnate Biopharma Inc.
